Top

Published in:

01-12-2013 | Benign Prostatic Hyperplasia (K McVary and S Kaplan, Section Editors)

Promising Molecular Targets and Biomarkers for Male BPH and LUTS

Authors: Mehrnaz Gharaee-Kermani, Jill A. Macoska

Published in: Current Urology Reports | Issue 6/2013

Abstract

Benign prostatic hyperplasia (BPH) is a major health concern for aging men. BPH is associated with urinary voiding dysfunction and lower urinary tract symptoms (LUTS), which negatively affects quality of life. Surgical resection and medical approaches have proven effective for improving urinary flow and relieving LUTS but are not effective for all men and can produce adverse effects that require termination of the therapeutic regimen. Thus, there is a need to explore other therapeutic targets to treat BPH/LUTS. Complicating the treatment of BPH/LUTS is the lack of biomarkers to effectively identify pathobiologies contributing to BPH/LUTS or to gauge successful response to therapy. This review will briefly discuss current knowledge and will highlight new studies that illuminate the pathobiologies contributing to BPH/LUTS, potential new therapeutic strategies for successfully treating BPH/LUTS, and new approaches for better defining these pathobiologies and response to therapeutics through the development of biomarkers and phenotyping strategies.

McVary KT. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther. 2007;29(3):387–98.PubMedCrossRef

Laborde EE, McVary KT. Medical management of lower urinary tract symptoms. Rev Urol. 2009;11:S19–25. suppl.PubMed

Barry MJ, Fowler Jr FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–57.PubMed

Barry MJ, Fowler Jr FJ, O'Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care. 1995;33(4 Suppl):AS145–55.PubMed

Zhang A, Sun H, Wang P, Han Y, Xijun X. Recent and potential developments of biofluid analyses in metabolomics. J Proteome. 2012;75(4):1079–88.CrossRef

Lubahn DB, Joseph DR, Sar M, et al. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol. 1988;2:1265–75.PubMedCrossRef

Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem. 2003;253:89–101.PubMedCrossRef

Rittmaster RS. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab. 2008;22:389–402.PubMedCrossRef

Weisser H, Tunn S, Debus M, et al. 5Alpha-reductase inhibition by finasteride (Proscar) in epithelium and stroma of human benign prostatic hyperplasia. Steroids. 1994;59:616–20.PubMedCrossRef

10.

• Bae JS, Park HS, Park JW, Li SH, Chun YS. Red ginseng and 20(S)-Rg3 control testosterone-induced prostate hyperplasia by deregulating androgen receptor signaling. Nat Med. 2012;66:476–85. This study found that the Phytotherapeutic agent (red ginseng) represses androgen-promoted prostate hyperplasia by blocking androgen receptor (AR) signaling and inhibited androgen-mediated prostate cell growth by enhancing degradation of the AR protein. Since currently many American men choose nonsurgical therapy for BPH, herbal preparations with red ginseng could be potential therapeutic agents for treating BPH.CrossRef

11.

Buck AC. Phytotherapy for the prostate. Br J Urol. 1996;78:325–3266.PubMedCrossRef

12.

Bales GT, Christiano AP, Kirsh EJ, Gerber GS. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urology. 1999;54:86–9.PubMedCrossRef

13.

Gravas S, Oelke M. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol. 2010;28:9–15.PubMedCrossRef

14.

Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354:557–66.PubMedCrossRef

15.

Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA. 2011;306:1344–51.PubMedCrossRef

16.

MacDonald R, Tacklind JW, Rutks I, Wilt TJ. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJUI. 2012;10(9):1756–61.CrossRef

17.

Bayne CW, Ross M, Donnelly F, Habib FK. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol. 2000;164:876–81.PubMedCrossRef

18.

Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, Lopez Farre A. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549–55.PubMedCrossRef

19.

Perry R, Milligan G, Anderson P, Gillon A, White M. Real-world use of Permixon® in benign prostatic hyperplasia-determining appropriate monotherapy and combination treatment. Adv Ther. 2012;29(6):538–50.PubMedCrossRef

20.

Wong SY, Lau WW, Leung PC, Leung KC, WOO J. The association between isoflavone and lower urinary tract symptoms in elderly men. Br J Nutr. 2007;98:1237–42.PubMedCrossRef

21.

Evans BA, Griffiths K, Morton MS. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol. 1995;147:295–302.PubMedCrossRef

22.

Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet. 1993;342:1209–10.PubMedCrossRef

23.

Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer: geographical distribution and time-trends. Acta Oncol. 1991;30:133–4.PubMedCrossRef

24.

Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl. The long-term outcome of medical therapy for BPH. Eur Urol. 2007;51:1522–33.PubMedCrossRef

25.

Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest updated on α1-adrenoceptor antagonists. BJUI. 2005;95 Suppl 4:29–36.CrossRef

26.

Michel MC, Bressel HU, Mehlburger L, Goepel M. Tamsulosin: Real life clinical experience in 19,365 patients. Eur Urol. 1998;34(2 suppl):37–45.PubMedCrossRef

27.

Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46–53.PubMedCrossRef

28.

Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol. 2005;174:1334–8.PubMedCrossRef

29.

Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296:2319–28.PubMedCrossRef

30.

Lee SH, Chung BH, Kim SJ, et al. Initial combined treatment with anticholinergics and a-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer Prostatic Dis. 2011;14:320–5.PubMedCrossRef

31.

Bae WJ, Bae JH, Choi YS, et al. Long-term alpha-blockers and anticholinergic combination treatment for men with lower urinary tract symptoms in real-life practice. Int Urol Nephrol. 2012;44:1077–84.PubMedCrossRef

32.

Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJUI. 2011;109:831–40. 1.

33.

Filippi S, Morelli A, Sandner P, et al. Characterization and functional role of androgen dependent PDE5 activity in the bladder. Endocrinology. 2007;148:1019–29.PubMedCrossRef

34.

Fibbi B, Morelli A, Vignozzi L, Filippi S. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med. 2010;71:59–69.CrossRef

35.

Gacci M, Ierardi A, Rose AD, Tazzioli S, et al. Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: Results of a randomized, double blind, placebocontrolled pilot study. J Sex Med. 2010;7(1Pt1)):234–43.PubMedCrossRef

36.

Gacci M, Vittori G, Tosi N, et al. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9:1624–33.PubMedCrossRef

37.

•• Gaccia M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61:994–1003. This study conducted a systematic review and meta-analysis of available prospective and cross-sectional studies on the use of phosphodiesterase 5 inhibitors (PDE5-Is) alone or in combination with α1-adrenergic receptor blockers in patients with BPH/LUS. The combined findings of this study supported a role for PDE5-I therapy for successful treatment of LUTS and erectile dysfunction in men with BPH.CrossRef

38.

Van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn. 2002;21:179–83.PubMedCrossRef

39.

Yu HJ, Chen FY, Huang PC, et al. Impact of nocturia on symptom-specific quality of life among community-dwelling adults aged 40 years and older. Urology. 2006;67:713–8.PubMedCrossRef

40.

Ancoli-Israel S, Bliwise DL, Nørgaard JP. The effect of nocturia on sleep. Sleep Med Rev. 2011;15:91–7.PubMedCrossRef

41.

Smith AL, Wein J. Outcomes of pharmacological management of nocturia with non-antidiuretic agents: does statistically significant equal clinically significant. BJUI. 2011;107:1550–4.CrossRef

42.

Koseoglu H, Aslan G, Ozdemir I, Esen A. Nocturnal polyuria in patients with lower urinary tract symptoms and response to alpha-blocker therapy. Urology. 2006;67:1188–92.PubMedCrossRef

43.

Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJUI. 2002;89:855–62.CrossRef

44.

Lose G, Mattiasson A, Walter S. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol. 2004;172:1021–5.PubMedCrossRef

45.

Van Kerrebroeck P, Rezapour M, Cortesse A, et al. Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study. Eur Urol. 2007;52:221–9.PubMedCrossRef

46.

Weiss JP, Zinner NR, Klein BM, Nørgaard JP. Orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012;31:441–7.PubMedCrossRef

47.

•• Chen Y, Zhang X, Hu X, et al. The potential role of a self-management intervention for benign prostate hyperplasia. Urology. 2012;79:1385–9. This article elegantly describes the important role of self-management for control of lower urinary tract symptoms (LUTS). It reinforces the role of patient education and initiatives in improving patient compliance with lifestyle and behavioral changes. It reported that the storage symptoms of urgency and nocturia were most improved by self-management intervention, consistent with the implication that fluid management, caffeine avoidance, and bladder retraining are the main effectors of improvement. This observation is important for management of LUTS.PubMedCrossRef

48.

Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Ex Med. 2011;208:1339–50.CrossRef

49.

Gharaee-Kermani M, Hu B, Phan SH, Gyetko MR. Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFβ signaling and the myofibroblast. Curr Med Chem. 2009;16:1400–17.PubMedCrossRef

50.

Gharaee-Kermani M, Hu B, Phan SH, Gyetko MR. The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy. Expert Opin Investig Drugs. 2008;17:905–16.PubMedCrossRef

51.

Gharaee-Kermani M, Hu B, Thannickal VJ, Phan SH, Gyetko MR. Current and emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2007;12:627–46.PubMedCrossRef

52.

Gharaee-Kermani M, Gyetko MR, Hu B, Phan SH. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm Res. 2007;24(5):819–41.PubMedCrossRef

53.

Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–18.PubMed

54.

•• Gharaee-Kermani M, Rodriguez-Nieves JA, Mehra R, et al. Obesity-induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse model. Prostate. 2013. doi:10.1002/pros.22662. Published online. This study was designed to test whether senescence-accelerated mouse prone 6 mice, which were reported to develop prostatic fibrosis, would also develop lower urinary tract symptoms and whether these symptoms would be exacerbated by diet-induced obesity and concurrent type 2 diabetes mellitus (T2DM). It was the first work to demonstrate the acquisition of urinary voiding dysfunction concurrent with obesity-induced T2DM and lower urinary tract fibrosis in animal model. This study found the link between diet, T2DM, fibrosis, and lower urinary tract dysfunction. Therefore, this study has significant clinical relevance for health and diseases.PubMed

55.

•• Ma J, Gharaee-Kermani M, Kunju L, et al. Prostatic fibrosis is associated with lower urinary tract symptoms. J Urol. 2012;188:1375–81. This paper addressed the basic science question of aging-associated fibrotic changes in tissue architecture contributing to dysfunction in lower urinary tract systems. This field has significant clinical relevance. This study were designed to test whether fibrotic changes potentially play a role in impaired urethral function and the development of lower urinary tract dysfunction (LUTD) in men. It was the first work to demonstrate that fibrotic changes affecting periurethral prostatic tissues are associated with increased mechanical stiffness, low elastin content, increased collagen content, inflammation, and symptomatic LUTD. This study explored a new paradigm that incorporates fibrosis as a contributing factor to urinary dysfunction, LUTD development, and progression of disease. These data suggest that in patients with LUTD associated with periurethral tissue fibrosis, antifibrotic therapeutics may provide benefits when used alone or in combination with the currently prescribed regimen.PubMedCrossRef

56.

•• Gharaee-Kermani M, Kasina S, Moore BB, et al. CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS One. 2012;7(11):e49278. This study was the first work to demonstrate that inflammatory proteins, particularly CXC-type chemokines, could mediate myofibroblast phenoconversion and the extra-cellular matrix deposition necessary for the development of prostatic tissue fibrosis. This paper showed that CXC-type chemokines, particularly CXCL12, can efficiently and completely mediate myofibroblast phenoconversion in the absence of TGFβ and may, thereby, promote fibrotic changes in prostate tissue architecture associated with the development and progression of male lower urinary tract dysfunction. These findings were important because they showed that CXC-type chemokines, which comprise inflammatory proteins known to be highly expressed in the aging prostate, can efficiently and completely mediate myofibroblast phenoconversion. Therefore, these molecules may comprise therapeutic targets for treating the initiation or progression of lower urinary tract symptoms development.PubMedCrossRef

57.

Pohlers D, Brenmoehl J, Loffler I, et al. TGF-beta and fibrosis in different organs-molecular pathway imprints. Biochim Biophys Acta. 2009;1792:746–56.PubMedCrossRef

58.

Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210.PubMedCrossRef

59.

St Sauver JL, Jacobson DJ, McGree ME, et al. Longitudinal association between prostatitis and development of benign prostatic hyperplasia. Urology. 2008;71:475–9.PubMedCrossRef

60.

Krieger JN, Lee SW, Jeon J, et al. Epidemiology of prostatitis. Int J Antimicrob Agents. 2008;31:S85. suppl.PubMedCrossRef

61.

Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJUI. 2013;Apr 12. doi:10.1111/bju.12118. [Epub ahead of print].

62.

Robert G, Descazeaud A, Nicolaiew N, et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate. 2009;69:1774–80.PubMedCrossRef

63.

Delongchamps NB, de la Roza G, Chandan V, et al. Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol. 2008;179:1736–40.PubMedCrossRef

64.

Bierhoff E, Vogel J, Benz M, et al. Stromal nodules in benign prostatic hyperplasia. Eur Urol. 1996;29:345–54.PubMed

65.

Verrecchia F, Mauviel A. Transforming growth factor-β and fibrosis. World J Gastroenterol. 2007;13:3056–62.PubMed

66.

•• Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028–40. This article elegantly describes the interesting topic about fibrosis and is pertinent to many basic science researchers, as well as clinicians. This article is an expert review describing the important topic of fibrosis in many tissue and organ systems. This article represents a uniquely comprehensive review of the new concepts behind the pathogenesis and treatment options both currently and in the future for fibrosis. The article points to the immune system contribution to the pathogenesis of fibrosis. This paper also represents a uniquely comprehensive review of the recent advances regarding the major key mechanisms and pathways of fibrosis that are being targeted as potential therapies for a variety of human fibrotic diseases.PubMedCrossRef

67.

Huang X, Lee C. Regulation of stromal proliferation, growth arrest, differentiation and apoptosis in benign prostatic hyperplasia by TGF-beta. Front Biosci. 2003;8:s740–9.PubMedCrossRef

68.

San Francisco IF, DeWolf WC, Peehl DM, Alumi A. Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer. 2004;112:213–8.PubMedCrossRef

69.

Kramer G, Mitteregger D, Marberger M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Eur Urol. 2007;51(5):1202–16.PubMedCrossRef

70.

Selman M, Ruiz V, Cabrera S, et al. TIMPs-1, -2, -3, and −4 in idiopathic pulmonary fibrosis. Am J Physiol. 2000;279:L562–74.

71.

Kunugi S, Fukuda Y, Ishizaki M, Yamanaka N. Role of MMP-2 in alveolar epithelial cell repair after bleomycin administration in rabbits. Lab Investig. 2001;81:1309–18.PubMedCrossRef

72.

Mcguire JK, Li Q, Parks WC. Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol. 2003;162:1831–43.PubMedCrossRef

73.

Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med. 1994;331(19):1286–92.PubMedCrossRef

74.

Bonniaud P, Margetts PJ, Kolb M, et al. Progressive transforming growth factor β1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med. 2005;171(8):889–98.PubMedCrossRef

75.

Cutroneo KR, White SL, Phan SH, Ehrlich HP. Therapies for bleomycin induced lung fibrosis through regulation of TGF-β1 induced collagen gene expression. J Cell Physiol. 2007;211:585–9.PubMedCrossRef

76.

Wei X, Xia Y, Li F, et al. Kindlin-2 mediates activation of TGF-β/Smad signaling and renal fibrosis. J Am Soc Nephrol. 2013;May 30. [Epub ahead of print].

77.

Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum. 2005;52(3):710–21.PubMedCrossRef

78.

Kajstura J, Pertoldi B, Leri A, et al. Telomere shortening is an in vivo marker of myocyte replication and aging. Am J Pathol. 2000;156:813–9.PubMedCrossRef

79.

Bavik C, Coleman I, Dean JP, et al. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 2006;66:794–802.PubMedCrossRef

80.

Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr Opin Investig Drugs. 2006;7:513–21.PubMed

81.

Tsuchida K, Sunada Y, Noji S, et al. Inhibitors of the TGF-beta superfamily and their clinical applications. Mini-Rev Med Chem. 2006;6:1255–61.PubMedCrossRef

82.

de Gouville AC, Huet S. Inhibition of ALK5 as a new approach to treat liver fibrotic diseases. Drug News Perspect. 2006;19:85–90.PubMedCrossRef

83.

Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int. 2006;26:8–22.PubMedCrossRef

84.

Behr J. Evidence-based treatment strategies in idiopathic pulmonary fibrosis. Eur Respir. 2013;22(128):163–8.CrossRef

85.

Phillips RJ, Burdick MD, Hong K, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004;114:438–46.PubMed

86.

• Makino H, Aono Y, Azuma M, et al. Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice. J Med Investig. 2013;60(1–2):127–37. The aim of this study was to define the role of the CXCL12–CXCR4 axis in the pathogenesis of lung fibrosis. It proposed that blockade of CXCR4 might inhibit the migration of fibrocytes to the injured lungs and the subsequent lung fibrosis. It was observed that the blockade of CXCR4 with specific molecule CXCR 4 antagonist, AMD3100, inhibits the fibrotic lesion in animal model of lung fibrosis. Thus, CXCR4 inhibitors might be a useful strategy for therapy of patients with fibrotic diseases.

87.

•• Nicholson JK, Holmes E, Kinross JM, et al. Metabolic phenotyping in clinical and surgical environments. Nature. 2012;491(7424):384–92. This article reports direct applications of metabolic phenotyping in a clinical setting, which has significant clinical implications. This technology allows analysis of biochemical classification of patient biology/pathology related to disease diagnosis or prognosis at the individual level and to disease risk factors at the population level. This technology provides important information on patient biology that enhances diagnosis of disease.PubMedCrossRef

88.

Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53:581–9.PubMedCrossRef

89.

Wright EJ, Fang J, Metter EJ, et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol. 2002;167:2484–7. discussion 2487–2488.PubMedCrossRef

90.

Pinsky PF, Kramer BS, Crawford ED, et al. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology. 2006;68:352–6.PubMedCrossRef

91.

Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268–78.PubMedCrossRef

92.

van Gils MP, Stenman UH, Schalken JA, et al. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol. 2005;48:1031–41.PubMedCrossRef

93.

Agarwal M, He C, Siddiqui J, Wei JT, Macoska JA. CCL11 (Eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate. 2013;73(6):573–81.

94.

Roos RS, Loetscher M, Legler DF, et al. Identification of CCR8, the receptor for the human CC chemokine I-309. J Biol Chem. 1997;272(28):17251–4.PubMedCrossRef

95.

Penna G, Mondaini N, Amuchastegui S, et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol. 2007;51(2):524–33.PubMedCrossRef

96.

Miller MD, Krangel MS. The human cytokine I-309 is a monocyte chemoattractant. Proc Natl Acad Sci U S A. 1992;89(7):2950–29544.PubMedCrossRef

97.

Zingoni A, Soto H, Hedrick JA, et al. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol. 1998;161(2):547–51.PubMed

98.

Kramer G, Mitteregger D, Marberger M. Is Benign Prostatic Hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51(5):1202–16.PubMedCrossRef

99.

•• McDowell KL, Begley LA, Mor-Vaknin N, Markovitz DM, Macoska JA. Leukocytic promotion of prostate cellular proliferation. Prostate. 2010;70(4):377–89. This study developed an in vitro system to mimic the human prostatic microenvironment that incorporates prostatic cells and inflammatory infiltrate. It showed that both aging stroma and malignant prostatic epithelial cells express chemoattractants that induce migration of inflammatory cells to prostate cells. This study showed a role for inflammatory infiltrate in the promotion of both benign and malignant cells in the prostate.PubMed

Title: Promising Molecular Targets and Biomarkers for Male BPH and LUTS
Authors: Mehrnaz Gharaee-Kermani
Jill A. Macoska
Publication date: 01-12-2013
Publisher: Springer US
Published in: Current Urology Reports / Issue 6/2013
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-013-0368-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Promising Molecular Targets and Biomarkers for Male BPH and LUTS

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

Understanding Clinic Options for Overactive Bladder

Mirabegron for Male Lower Urinary Tract Symptoms

The Evaluation and Management of Testosterone Deficiency: the New Frontier in Urology and Men’s Health

The Evaluation and Treatment of Prostate-Related LUTS in the Primary Care Setting: The Next STEP

Urethral Lift for Benign Prostatic Hyperplasia: A Comprehensive Review of the Literature

The use of PDE-5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia